US Patent Issued to Jiangsu Hengrui Medicine, Suzhou Suncadia Biopharmaceuticals on March 4 for "Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors" (Chinese Inventors)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,240,904, issued on March 4, was assigned to Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, China) and Suzhou Suncadia Biopharmaceuticals Co. Ltd. (Jiangsu, China).

"Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors" was invented by Lianshan Zhang (Jiangsu, China), Qing Yang (Jiangsu, China), Quanren Wang (Jiangsu, China), Xiaoxing Huang (Jiangsu, China), Cheng Liao (Jiangsu, China), Changyong Yang (Jiangsu, China), Dingwei Ye (Jiangsu, China) and Xiaohua Wu (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides the use of an anti-PD-1 antibody in combination with famit...